Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H19BrF2N2O3 |
Molecular Weight | 477.299 |
Optical Activity | NONE |
Additional Stereochemistry | Yes |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
Stereo Comments | AXIAL, S |
SHOW SMILES / InChI
SMILES
CNC(=O)C1=CC(N2C(C)=CC(OCC3=CC=C(F)C=C3F)=C(Br)C2=O)=C(C)C=C1
InChI
InChIKey=KCAJXIDMCNPGHZ-UHFFFAOYSA-N
InChI=1S/C22H19BrF2N2O3/c1-12-4-5-14(21(28)26-3)9-18(12)27-13(2)8-19(20(23)22(27)29)30-11-15-6-7-16(24)10-17(15)25/h4-10H,11H2,1-3H3,(H,26,28)
Molecular Formula | C22H19BrF2N2O3 |
Molecular Weight | 477.299 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
PH-797804 is a diarylpyridinone inhibitor of p38alpha mitogen-activated protein. The drug was developed by Pfizer for the treatment of inflammatory diseases. PH-797804 is being tested in phase II of clinical trials in patients with COPD, osteoarthritis, rheumatoid arthritis and post-herpetic neuralgia.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL260 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21641211 |
2.3 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase. | 2011 Jul 1 |
|
Substituted N-aryl-6-pyrimidinones: a new class of potent, selective, and orally active p38 MAP kinase inhibitors. | 2011 Jul 1 |
|
Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease. | 2011 Nov 24 |
Patents
Sample Use Guides
Chronic Obstructive Pulmonary Disease: PH-797804 should be orally administered at maximum dose of 10 mg. Neuralgia: 6 mg dose in oral capsule form, once daily for 28 days. Osteoarthritis: 6 mg once daily for 2 weeks. Rheumatoid Arthritis: the maximum dose is 10 mg taken once daily for 12 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19720877
Rheumatoid arthritis synovial fibroblasts were treated with serial concentrations (10000–0.01 nM) of PH-797804 for 1 h, stimulated with 1 ng/ml IL-1 for 18 to 20 h at 37C to measure IL-1-beta induced PGE2 production. IC50 was 1.5 nM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 14:12:19 GMT 2023
by
admin
on
Sat Dec 16 14:12:19 GMT 2023
|
Record UNII |
GEL7GRJ3R6
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
586414-48-4
Created by
admin on Sat Dec 16 14:12:19 GMT 2023 , Edited by admin on Sat Dec 16 14:12:19 GMT 2023
|
SUPERSEDED | |||
|
1358027-80-1
Created by
admin on Sat Dec 16 14:12:19 GMT 2023 , Edited by admin on Sat Dec 16 14:12:19 GMT 2023
|
PRIMARY | |||
|
DB07941
Created by
admin on Sat Dec 16 14:12:19 GMT 2023 , Edited by admin on Sat Dec 16 14:12:19 GMT 2023
|
PRIMARY | |||
|
GEL7GRJ3R6
Created by
admin on Sat Dec 16 14:12:19 GMT 2023 , Edited by admin on Sat Dec 16 14:12:19 GMT 2023
|
PRIMARY | |||
|
22049997
Created by
admin on Sat Dec 16 14:12:19 GMT 2023 , Edited by admin on Sat Dec 16 14:12:19 GMT 2023
|
PRIMARY |